Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human anti-tetanus toxin monoclonal antibody B86
- Development stage
- Unknown
- Lead developer
- Changchun BCHT Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
Human anti-tetanus toxin monoclonal antibody B86 is a fully human monoclonal antibody developed to neutralize tetanus toxin, the neurotoxin produced by *Clostridium tetani*. It is designed for passive immunization and treatment of tetanus, acting as an inhibitor of the tetanus toxin. The mechanism involves direct binding to and neutralization of the neurotoxin, thereby preventing its interaction with neuronal targets and blocking its toxic effects. This drug is being developed as part of a combination formulation (A82/B86) for enhanced efficacy in neutralizing different domains or epitopes on the tetanus toxin. The primary indication is prophylaxis and treatment of tetanus, especially in individuals at risk or exposed to *C. tetani* who require rapid passive immunity[1].
- Other names
- human anti-tetanus toxin monoclonal antibody B86
Beyond the preview
Go deeper on human anti-tetanus toxin monoclonal antibody B86.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human anti-tetanus toxin monoclonal antibody B86.